Biocon's Biosimilar Yesafili™ Data Published in Top Journals
Biocon's aflibercept biosimilar, Yesafili™, has had pivotal clinical data published in the British Journal of Ophthalmology and Expert Opinion on Biological Therapy. The studies support its effectiveness for diabetic macular edema (DME) and show comparability to reference aflibercept. This milestone aids Biocon's upcoming U.S. launch.
The publication of clinical data is a positive development that supports the company's biosimilar program and upcoming launch in the U.S. However, the immediate financial impact is not directly quantifiable from this announcement alone, placing it at a medium level.
The publication of positive clinical data in peer-reviewed journals for a key biosimilar product is a significant achievement that supports the company's development and upcoming launch, indicating progress and potential market success.
Biocon Limited announced the publication of pivotal clinical data supporting the effectiveness of Yesafili™ (aflibercept-jbvf), a biosimilar to Eylea® (aflibercept). The data, from the Phase III INSIGHT program evaluating MYL-1701P, were published in the British Journal of Ophthalmology on June 29, 2026, and Expert Opinion on Biological Therapy on May 18, 2026.
The study in the British Journal of Ophthalmology demonstrated that patients continuing on MYL-1701P and those switching from reference aflibercept showed similar safety, efficacy, and immunogenicity outcomes through a 20-week extension, maintaining visual and anatomic results. The publication in Expert Opinion on Biological Therapy presented subgroup analyses showing MYL-1701P had comparable improvements in visual acuity and retinal thickness to reference aflibercept across diverse diabetic macular edema (DME) populations.
Shreehas Tambe, CEO & Managing Director, Biocon, stated that these findings are an important milestone for their aflibercept biosimilar program as they prepare for launch in the United States, emphasizing the company's commitment to expanding access to biosimilars. Dr. Elena Wolff-Holz, Chief Medical Officer, Biocon, added that the data reinforce the clinical evidence and demonstrate consistency of outcomes and comparability across relevant patient subgroups, supporting MYL-1701P as a reliable treatment option for DME.
Yesafili™ received approval and an interchangeable designation from the U.S. Food and Drug Administration in May 2024. It is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.